TMDX
Research Snapshot
Static fundamentals, valuation context, and investor signals for TransMedics Group, Inc. (TMDX).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
40.2%
ROIC, 22.1% FCF margin
Growth
84.5%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 7.1x current ratio
Superinvestors
1
Top: Polen Capital Management (0.0%)
Strengths to research
- Revenue compounded at 84.5% over five years.
- Return on equity is strong at 40.2%.
- Free cash flow margin is healthy at 22.1%.
- Debt/equity looks manageable at 0.0x.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 8 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for TMDX.
Grade D
41
/ 100
Financial Charts
No financial data available for TMDX (annual).
1 superinvestors own TMDX
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 7,422 | $738,000 | 0.01% | 0.0% |